[2]. Kallubai M, et, al. Spectroscopic evaluation of synthesized 5β-dihydrocortisol and 5β-dihydrocortisol acetate binding mechanism with human serum albumin and their role in anticancer activity. J Biomol Struct Dyn. 2019 Feb;37(3):623-640.
[3]. Southren AL, et, al. 5 beta-Dihydrocortisol: possible mediator of the ocular hypertension in glaucoma. Invest Ophthalmol Vis Sci. 1985 Mar;26(3):393-5.
[4]. Appanna N, et, al. Differential activity and expression of human 5β-reductase (AKR1D1) splice variants. J Mol Endocrinol. 2021 Mar;66(3):181-194.
[5]. Weinstein BI, et, al. Potentiation of glucocorticoid activity by 5 beta-dihydrocortisol: its role in glaucoma. Science. 1983 Oct 14;222(4620):172-3.
[1]. Marver D, et, al. Dihydrocortisol: a potential mineralocorticoid. J Steroid Biochem. 1978 Jan;9(1):1-7.
[1]. Marver D, et, al. Dihydrocortisol: a potential mineralocorticoid. J Steroid Biochem. 1978 Jan;9(1):1-7.
[2]. Kallubai M
安全信息
RTECS
TU4158700
TYPE OF TEST : DNA adduct
TEST SYSTEM : Human Liver
DOSE/DURATION : 2 mmol/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE
Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 370,49,1996